

## Carboxylate BODIPY integrated in MOF-5: easy preparation and solid state luminescence

Alexis Tran<sup>a</sup>, Marion Leroux<sup>a</sup>, Clément Michelin<sup>a</sup>, François Réveret<sup>a</sup>, Damien Boyer<sup>a</sup>, Federico Cisnetti<sup>\*a</sup>

Université Clermont Auvergne, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand. \* [federico.cisnetti@uca.fr](mailto:federico.cisnetti@uca.fr)

### Supporting Information

#### Contents

**Table S1:** Relevant literature comparisons

**Fig. S1:** <sup>1</sup>H and <sup>13</sup>C NMR spectra of organic compounds

**Fig. S2:** MOF@BP-COO<sup>-</sup> samples after synthesis and centrifugation under daylight.

**Fig. S3:** MOF@BP-COO<sup>-</sup> samples after synthesis and centrifugation under 365 nm UV lamp.

**Fig. S4:** Structure of BP2, its excitation and emission ( $\lambda_{exc} = 504$  nm) spectra in EtOH.

**Fig. S5:** first and second supernatant for the attempted synthesis of MOF@BP2 under UV at 365 nm. MOF-5 after centrifugation in the centrifugation tube (not luminescent).

**Fig. S6:** Evolution of the emission spectra ( $\lambda_{ex} = 525$  nm) of the MOF@BP-COO<sup>-</sup><sub>10.6%</sub> sample after several hours in chloroform.

**Fig. S7:** Adsorption and desorption isotherms of the MOF-5 and the MOF@BP-COO<sup>-</sup><sub>10.6%</sub> sample.

**Fig. S8:** Evolution of the absorption spectra of BP-COO<sup>-</sup> in solution (DMF/Et<sub>3</sub>N; 75/1; v/v) after 3 months

**Fig. S9:** Absorbance standard curve of BP-COO<sup>-</sup> in solution (DMF/Et<sub>3</sub>N; 75/1; v/v) as function of the concentration

**Fig. S10:** Absorbance standard curve of BP-COO<sup>-</sup> in KBr pellets as function of the mass % of BP-COOH in the pellets

**Fig. S11:** Evolution of the PLQY<sub>int</sub>, the absorption and the PLQY<sub>abs</sub>, as function of the excitation wavelength for the different MOF@BP-COO<sup>-</sup><sub>x%</sub> samples

**Fig. S12:** TGA analysis of the MOF@BP-COO<sup>-</sup><sub>10.6%</sub> and the MOF-5.

**Fig. S13:** Diffractogram of MOF@BP-COO<sup>-</sup><sub>10.6%</sub> after 2h30 and 8h of synthesis.







**Fig. S14:** Picture of BP2S-COOH in solid state and in solution (DMF/Et<sub>3</sub>N ; 75/1 ; v/v) under daylight and UV (365 nm).



**Fig. S15:** Picture of the MOF@BP2S-COO<sup>-</sup> synthesized under daylight and UV (365 nm).



**Fig. S16:** Absorbance standard curve of BP2S-COO<sup>-</sup> in solution (DMF/Et<sub>3</sub>N ; 75/1 ; v/v) function of the concentration.

**Fig. S17:** Evolution of the PLQY<sub>int</sub>, the absorption and the PLQY<sub>abs</sub>, as function of the excitation wavelength for the MOF@BP2S-COO<sup>-</sup><sub>5.2%</sub>


**Table S1: Relevant literature comparisons**

Reference	BODIPY (and other strut(s) if present)	Metal ion(s)	Synthetic method	PLQY or other luminescence property reported
Ref 17	 HOOC-COOH	Zn <sup>2+</sup> , Cd <sup>2+</sup>	Direct Solvothermal synthesis (presence of acid)	< 2% PLQY <sub>int</sub>
Ref 18	 1,4-benzenedicarboxylic acid or 1,3,5-benzenetricarboxylic acid	Zn <sup>2+</sup> , Cd <sup>2+</sup>	Direct Solvothermal synthesis (presence of acid)	PLQY not reported (“strong photoluminescence”)
Ref 19	 4,4'-biphenyldicarboxylic acid	Zn <sup>2+</sup>	Direct solvothermal synthesis (presence of acid)	PLQY not reported (scope of ref. 19 is photocatalysis)
Ref 20	 anthracene dicarboxylic acid	Zn <sup>2+</sup>	Direct solvothermal synthesis (presence of acid)	0.5% PLQY (upon excitation of the anthracene moiety, no other data reported)
Ref. 21	 ,4-dibromo-2,3,5,6-tetrakis(4-carboxyphenyl)benzene or tetraacid porphyrin)	Zn <sup>2+</sup>	Direct solvothermal synthesis (presence of acid). Delayed addition of BODIPY in the case of porphyrin	PLQY not reported (energy transfer from BODIPY to porphyrin evidenced)
Ref 25	 terephthalic acid (preformed UiO-66)	Zr <sup>4+</sup> (preformed UiO-66)	Ligand exchange	PLQY not reported (scope of ref 25 is X-ray tomography)
Ref. 26	BP-alkyne and azide-functionalized 1,3,5-benzenetricarboxylic acid derivative (preformed PCN-262 derivative)	Fe <sup>3+</sup> (preformed PCN-262 derivative)	Copper-catalysed azide alkyne cycloaddition on preformed MOF	PLQY not reported (fluorescence enhancement after reaction demonstrated)





BP2S-COOMe:  $^1\text{H}$  NMR spectrum



BP2S-COOH:  $^{13}\text{C}$  NMR spectrum (APT)







Fig. S1:  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of organic compounds



**Fig. S2:** MOF@BP-COO<sup>-</sup> samples after synthesis and centrifugation under daylight.




**Fig. S3:** MOF@BP-COO<sup>-</sup> samples after synthesis and centrifugation under 365 nm UV lamp.




**Fig. S4:** Structure of BP2, its excitation ( $\lambda_{em} = 510$  nm) and emission ( $\lambda_{exc} = 504$  nm) spectra in EtOH at  $1.10^{-5}$  mol.L $^{-1}$ .



**Fig. S5:** From the right to the left: first and second supernatant for the attempted synthesis of MOF@BP2 under UV at 365 nm. MOF-5 after centrifugation in the centrifugation tube (not luminescent).




**Fig. S6:** Evolution of the emission spectra ( $\lambda_{\text{ex}} = 525 \text{ nm}$ ) of a MOF@BP-COO<sup>-</sup><sub>10.6%</sub> sample after several hours in chloroform.




**Fig. S7:** Adsorption and desorption isotherms of the MOF-5 and the MOF@BP-COO<sup>-</sup><sub>10.6%</sub> sample. The specific surface area for the MOF-5, measured by BET is 957 m<sup>2</sup>·g<sup>-1</sup> and 560 m<sup>2</sup>·g<sup>-1</sup> for the MOF@BP-COO<sup>-</sup><sub>10.6%</sub>.







**Fig. S8:** Evolution of the absorption spectra of BP-COO<sup>-</sup> in solution (DMF/Et<sub>3</sub>N: 75/1; v/v) after 3 months ( $3.4 \cdot 10^{-5} \text{ mol.L}^{-1}$  stock solution diluted 100 times).







**Fig. S9:** Absorbance standard curve at  $\lambda_{\text{max}}$  for BP-COO<sup>-</sup> in solution (DMF/Et<sub>3</sub>N; 75/1; v/v) as a function of the concentration




**Fig. S10:** Absorbance standard curve at  $\lambda_{\max}$  for BP-COO<sup>-</sup> in KBr pellets as a function of the mass % of BP-COOH in the pellets









**Fig. S11:** Evolution of PLQY<sub>int</sub>, the absorption coefficient and PLQY<sub>ext</sub>, as function of the excitation wavelength for the different MOF@BP-COO<sub>x%</sub> samples (A:  $x = 0.27\%$ , B:  $x = 2.7\%$ , C:  $x = 8.4\%$ , D:  $x = 10.6\%$ , E:  $x = 17.7\%$ ).




**Fig. S12:** TGA analysis of a MOF@BP-COO<sup>-</sup><sub>10.6%</sub> compared with a MOF-5 sample prepared in the same conditions.




**Fig. S13:** Diffractogram of MOF@BP-COO<sup>-</sup><sub>10.6%</sub> after 2h30 and 8h of synthesis.




**Fig. S14:** Picture of BP2S-COOH in solid state and in solution (DMF/Et<sub>3</sub>N; 75/1; v/v) under daylight and UV (365 nm).



**Fig. S15:** Picture of the synthesized MOF@BP2S-COO<sup>-</sup> under daylight and UV (365 nm).



**Fig. S16:** Absorbance standard curve at  $\lambda_{\max}$  for BP2S-COO<sup>-</sup> in solution (DMF/Et<sub>3</sub>N; 75/1; v/v) as a function of the concentration.



**Fig. S17:** Evolution of PLQY<sub>int</sub>, the absorption coefficient and PLQY<sub>ext</sub>, as function of the excitation wavelength for the MOF@BP2S-COO<sup>-</sup><sub>5.2%</sub>.